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Abstract.  To detect changes in the extent of tubulin 
polymerization in cultured cells, we have developed a 
radioactive antibody binding assay that can be used to 
quantitate total cytoskeletal tubulin or specific anti- 
genic subsets of polymerized tubulin.  Fibroblastic 
cells, grown to confluence in multiwell plates,  were 
permeabilized and extracted with 0.5 % Triton X-100 in 
a microtubule-stabilizing buffer. These extracted 
cytoskeletons were then fixed and incubated with 
translationally  radiolabeled monoclonal antitubulin an- 
tibody (Ab 1-1.1), an IgM antibody specific for the 
beta subunit of tubulin.  Specific binding of Ab 1-1.1 to 
the cytoskeletons was saturable and of a  single appar- 
ent affinity.  All specific binding was blocked by prein- 
cubation of the radiolabeled antibody with excess 
purified brain tubulin.  Specific Ab 1-1.1 binding 
appeared to represent binding to cytoskdetal tubulin 
inasmuch as:  (a) pretreatment of cells with colchicine 
decreased Ab 1-1.1 binding in a dose-dependent man- 
ner which correlated with the amount of polymerized 
tubulin visualized in parallel cultures by indirect 
immunofluorescence, (b) taxol pretreatment alone 
caused an increase in Ab 1-1.1 binding and prevented 
in a dose-dependent manner the colchicine-induced 
decrease in antibody binding,  (c) in cells pretreated 
with colcemid and returned to fresh medium,  Ab 1-1.1 
binding decreased and recovered in parallel with the 
depolymerization and regrowth of microtubules in 
these cells, and (d) comparison of maximal antibody 
binding per cell between primary mouse embryo, 3T3, 
and human foreskin fibroblasts correlated with im- 
munofluorescence visualization of microtubules in 
these cells. Thus,  this assay can be used to measure 
relative changes in the level of polymefized cytoskele- 
tal tubulin.  Moreover, by Scatehard-type analysis of 
the binding data it is possible to estimate the total 
number of antibody binding sites per cell.  Therefore, 
depending on the stoichiometry of antibody binding, 
this type of assay may be used for quantitating  total 
cytoskeletal tubulin,  specific antigenic subsets of 
cytoskeletal tubulin,  or other cytoskeletal proteins. 
M 
ICROTUBULES are tubular polymers whose proto- 
meric unit is a heterodimer consisting  of ¢t- and 
13-tubulin subunits  (for a recent review see refer- 
ence 20). The cytoplasm of eukaryotic cells contains  an or- 
ganized  array of microtubules as well as a soluble pool of 
unpolymerized  tubulin protomers.  These cytoplasmic micro- 
tubules  represent  a  dynamic dement  of the  cytoskeleton 
since microtubules can be rapidly assembled or disassem- 
bled in  response to  various  stimuli  with  little  or no  net 
change in the total tubulin content of the cell (24). Inou6 and 
Sato (17) demonstrated that the polymer and protomer forms 
of intracellular  tubulin are in a "dynamic equilibrium" which 
can be perturbed by changes in pressure. This equilibrium 
can also be perturbed by drugs such as colchicine and vin- 
blastine which induce microtubule disassembly in vivo (41), 
or by taxol, which stabilizes microtubules and promotes the 
assembly of supernumerary microtubules within  the cyto- 
plasm (21, 37). 
Cytoplasmic microtubules have been implicated in such 
diverse processes as cellular motility, intracdlular transport, 
secretion,  organization  of the cytoplasm,  organization  of 
proteins in the membrane, growth factor signalling, and may 
undergo changes related to transformation  (6, 10, U, 12-14, 
23). It has long been of interest  to determine if changes  in 
the extent of polymerization of tubulin are associated with 
such  processes.  Estimates  of cytoskeletal  tubulin  can  be 
made  either  directly,  by binding  reagents  specifically  to 
microtubules, or indirectly, by subtracting  the amount of un- 
polymerized tubulin from the total tubulin determined after 
depolymerization.  It has  been suggested  that  cytoskeletal 
tubulin can be quantitated  directly by binding  radiolabeled 
taxol to microtubules (27, 28), but an effective labeled re- 
agent is difficult to prepare and may bind differentially to cer- 
tain classes of microtubules (29).  In addition,  immunotluo- 
rescence techniques  with antitubulin  antibodies have been 
used to directly visualize cellular microtubules to document 
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munofluorescence  staining  of cytoskeletal  structures  has 
proved difficult to quantitate,  particularly for large popula- 
tions of cells. 
Among the indirect  methods of determining  cytoskeletal 
tubulin,  several protocols have been developed that use the 
binding of labeled colchicine to free tubulin promoters to es- 
timate the unpolymerized tubulin pool and the total tubulin 
in  a  tissue.  Cytoskeletal  tubulin is  then  estimated as the 
difference between these values (3, 4, 22, 25, 26, 30-33, 40). 
Traditional  radioimmunoassays  for unpolymerized tubulin 
have also been developed (15, 16, 18, 19, 39) that could theo- 
retically be used to estimate the cytoskeletal tubulin content 
of cells by a subtractive  method. 
We describe here a direct radioactive antibody binding as- 
say specific for cytoskeletal tubulin in cultured calls. Distinc- 
tion  between polymerized  and  unpolymerized  tubulin  is 
made by detergent-extraction  of the unpolymerized tubulin 
pool and other soluble cytoplasmic components before anti- 
body binding  to the insoluble cytoskeletons.  To ensure that 
the labeled binding reagent has a single affinity for tubulin, 
we have used a monoclonal antitubulin  antibody (Ab 1-1.1) 
which has been previously shown by indirect immunofluo- 
rescence  to  bind  to  all  microtubules  of the  cytoplasmic 
microtubule complex (37). By incorporating  other, more dis- 
criminatory,  antibody  reagents,  the  procedure  described 
here should also prove invaluable  for examining  the parti- 
tioning of antigenically  unique species of tubulin within cel- 
lular Ix>ols (37). 
Materials and Methods 
Materials 
Except as otherwise noted, reagent grade chemicals from Sigma Chemical 
Co. (St. Louis, MO) were used in these experiments. Taxol was provided 
by Dr. Matthew Suffness, Natural Products Branch, National Cancer Insti- 
tute, and was diluted in ethanol. Colehicine and ¢olcemid (demecolcine) 
were diluted in PBS without divalent cations. Polyacrylamide gel com- 
ponents were obtained from Bio-Rad Laboratories (Richmond, CA), ex- 
cept for the 95 % pure grade of sodium lanryl sulfate (Sigma Chemical 
Co.).  [3~S]Methionine  was purchased from Amersham Corp.  (Arlington 
Heights, IL) and 3H-amino acid mixture from ICN Radiochemicals (Div. 
ICN Biomedicals Inc., Irvine, CA). Horse serum was obtained from KC 
Biological Inc. (Lenexa, KS), calf serum from Irvine Scientific (Santa Ana, 
CA), and culture medium and supplements from Gibco (Grand Island, NY). 
Antibodies 
The monoclonal antitubulin Ab 1-1.1 used in this study has previously been 
shown by double-label immunofluorescence  to bind to all of  the cytoplasmic 
microtubules in mouse fibroblastic cells (37). As previously described, the 
hybridoma clone secreting Ab 1-I.I was derived from the fusion of a non- 
secreting murine myeloma cell and an immune splenocyte from a BALB/c 
mouse immunized with sea urchin axonemal proteins (1,  2).  Using an 
ELISA antibody typing kit  (Boehringer Mannheim Biochemicals, Indi- 
anapelis, IN), we determined Ab 1-1.1 to be an immunoglobulin of the IgM 
(kappa) class. Ascites serum containing high concentrations of unlabeled 
Ab 1-1.1 was obtained from pristane-primed BALB/c female mice bearing 
ascites tumors of the 1-1.1 hybridoma clone. For use in some experiments, 
as noted, an IgM fraction was isolated from the ascites fluid (5). 
Monoclonal antibody was translationally radiolabeled and secreted into 
the culture medium by cells of the 1-1.1 hybridoma clone during growth for 
24--30 h in RPMI 1640 medium supplemented with 15 % horse serum and 
containing 0.05  mCi/ml  of [3~Slmethionine  or  3H-amino  acid mixture. 
Cells were pelleted by centrifugation for 10 rain at 1,000 g, and the superna- 
tant medium was removed, dialyzed against several changes of 100 vol of 
PBS (Dulbecco's phosphate-buffered saline without divalent cations), filter 
sterilized, and used directly as a source of labeled Ab 1-1.1. Alternatively, 
an IgM  fraction was purified from the dialyzed culture  supernatant by 
Sepbacryl S-200 chromatography as described by Bouvet et al. (5).  This 
purified reagent was dialyzed overnight against PBS, filter sterilized, and 
stored at 40C for use as a stock of labeled Ab 1-1.1 for binding to microtu- 
bufes in extracted cytoskeletons. 
Immunoblotting 
Phosphocellulose-purified, thrice-cycled, mouse  brain  tubulin  and  total 
mouse embryo (ME)  1 cellular proteins were taken up in sample buffer and 
subjected to electrophoresis on 8% polyacrylamide gels according to the 
formulations of Sbeir-Neiss et al. (36). The resolved protein pattern was 
transferred by Western blotting (7, 38) to nitrocellulose paper (grade BA85, 
Schleicher & Schuell, Keene, NH). It was necessary to remove the SDS by 
soaking the nitrocellulose blot briefly in 1% Triton X-100 in PBS to allow 
efficient binding of Ab  1-1.1 to the denatured tubulin (suggested by Dr. 
Engenia Wang, Rockefeller University). The nitrocellulose was blocked by 
incubation for 1 h in a solution of 10% dried milk solids (Carnation) in Tris- 
buffered saline (I'BS): 150 mM NaCI, 10 mM Tris, pH 7.5. The nitrocellulose 
blot was then incubated for 2 h at room temperature with hybridoma culture 
supernatant containing Ab  1-1.1, rinsed, and incubated with peroxidase- 
conjugated goat anti-mouse antibodies (anti-IgG,  -IgA,  -IgM) obtained 
from Cappel Laboratories (Cochranvilfe, PA). After a final rinse with Tris- 
buffered saline, the pattern of bound antibody was developed by incubation 
with 0.07% 4-chloro-l-naphthol 0Bio-Rnd horseradish peroxidase color de- 
velopment reagent) and 0.02%  H202  in a  solution of 20%  methanol and 
80% Tris-buffered saline. 
Cell Culture 
Clone 1-1.1 murine hybridoma cells were cultured in plastic tissue culture 
flasks (75 cm  z) in RPMI 1640 medium supplemented with 15 % horse se- 
rum, penicillin (100 U/ml), and streptomycin (100 Ixg/ml) in a humidified 
atmosphere containing 7.5%  CO2.  Primary cultures of ME  fibroblastic 
cells, obtained by trypsinizatiun of the body wall of 9-11-d embryos as 
described (8),  were cultured  in  DV-FI2  medium (45%  Dulbecco-Vnght 
modified Eagle's medium, 45% Ham's FI2 medium, 10% calf serum, and 
antibiotics as above) in a humidified atmosphere containing 5 % CO2. Hu- 
man foreskin (HF) cells, prepared as described (8), and mouse 3T3 cells 
were  also maintained in  DV-FI2  medium.  Secondary cultures of these 
fibroblastic cells were plated either in 24- or 48-well tissue culture plates 
at an initial density of 5  x  104 cells/era  2. In most experiments, wells were 
precoated with 2 % gelatin. Because we are interested in using this assay for 
growth control studies in the future, confluent cultures of these fibroblastic 
cells were incubated in serum-free  DV-FI2 medium for 48 h to bring the cells 
to a quiescent Go state before the binding analysis. 
Binding of  Radioactive Antibody to 
Cytoskeletal Tubulin 
Confluent cultures of nonproliferating fibroblasts in multiweli culture plates 
were rinsed with warm microtubule-stabilizing buffer (MSB) containing 
I00 mM Pipes (pH 6.9), 1 mM EGTA, and 4% polyethylene glycol (PEG- 
3350).  The cell membranes were then permeabilized by incubation for 10 
rain at room temperature in 0.5 % Triton X-100 in MSB supplemented with 
the pmteolytic inhibitor aprotinin (0.1 trypsin inhibitor units/ml). The re- 
suiting cytoskeletons were rinsed three times in warm MSB to remove free 
tubulin, fixed for 10 rain in a solution of  4 % formaldehyde  (freshly prepared 
from paraformaldehyde) in warm MSB, and rehydrated in PBS before anti- 
body binding. This fixation procedure was found to be superior to methanol 
fixation. 
Fixed cytoskeletons were incubated with radiolabeled Ab I-I.1  (diluted 
in PBS containing 0.05 % Tween 20) at 4 °C overnight with continuous gentle 
agitation. After extensive washing of the culture plate in PBS to remove un- 
bound antibody, the bound radioactive antibody was released into  1.0 N 
NaOH at room temperature for 24 h. Samples were neutralized with HCI 
and were counted in 10 ml of Ready Solve MP-B (Beckman, Houston, TX). 
For determination of the nonspecific binding, 10 or 20 ttl of homologous 
ascites serum containing a large excess of unlabeled Ab 1-1.1 was added to 
wells of 48- or 24-well plates, respectively, immediately before addition of 
the labeled antibody. 
1. Abbreviations used in this paper: HE human foreskin; ME, mouse em- 
bryo; MSB, microtubule-stabilizing buffer. 
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An IgM fraction containing radiolabeled Ab 1-1.1 was isolated from hybrid- 
oma 1-1.1 culture supernalant by the method of Bouvet et al. (5). In this pro- 
cedure, the supernatant proteins are resolved by gel permeation chromatog- 
raphy on Sephacryl S-200 preequilibrated with a low ionic strength buffer 
and eluted with a high ionic strength buffer. IgM molecules, being englobu- 
lins, are not soluble in the low ionic strength buffer and, instead of eluting 
at the excluded volume, elute at the included volume with the high ionic 
strength buffer. The radioactive protein in this fraction co-migrates with the 
IgM heavy and light chains, but the fraction still contains some unlabeled 
serum proteins. Therefore, we have determined the protein content of only 
the active labeled Ab 1-1.1 molecules using data from saturation curves and 
competitive binding experiments where the concentration of highly purified 
unlabeled Ab lq.l is known. By determining the amount of unlabeled anti- 
body necessary to decrease the specific activity of the bound antibody by 
two-thirds, we calculated the concentration of active Ab 1-1.1 protein in the 
labeled supernatant fraction. The supernatant used for quantitation studies 
contained 101 lag of active antibody per milliliter with a specific activity of 
5.26  ×  10  ~ cpm/Ixg. 
Immunofluorescence 
For correlation of the binding experiments with indirect immunofluores- 
cence staining, cells were grown on glass coverslips (8.3  ×  l(P cells/cm  2) 
and brought to quiescence as described above. Cell membranes were per- 
meabilized and the resulting cytoskeletons fixed as in antibody binding as- 
says.  The coverslips were then rinsed in Ca  ++-, Mg++-free PBS and the 
cells incubated with one drop of undilute unlabeled hybridoma  1-1.1 su- 
pernatant  for  1  h  at 37°C.  After incubation,  the coverslips were  rinsed 
extensively in PBS and incubated as above with a fluorescein isothiocyanate- 
conjugated goat anti-mouse immunoglobulin (Kirkegaard & Perry Labora- 
tories, Inc., Gaithersburg, MD).  The coverslips were rinsed again in PBS 
and mounted on glass slides in 1 drop of 10% glycerol in borate saline. Cells 
were examined with a Leitz Orthoplan microscope with epifluorescent illu- 
mination and were photographed using Kodak Tri-X pan film pushed to ASA 
1600 with ethol blue. 
Results 
Characterization  of  Ab 1-1.1 
For  the  development  of this  antibody  binding  assay  for 
cytoskeletal tubulin, we have used an IgM monoclonal an- 
titubulin antibody designated Ab 1-1.1. The hybridoma clone 
secreting Ab 1-1.1 was derived from the fusion of an M5 mu- 
rine myeloma cell and a splenocyte from a mouse previously 
immunized with an extract of sea urchin (Strongylocentrotus 
purpuratus) sperm tail axonemal proteins as described (1, 2). 
This  antibody  has  been  shown  by  immunofluorescence 
studies  to  bind  to  all  microtubules  in  the  cytoplasmic 
microtubule complex of mouse fibroblasts (37).  To deter- 
mine  if this  monoclonal antibody might bind to  proteins 
other than tubulin, purified tubulin and total ME cell pro- 
teins were subjected to electrophoresis, blotted to nitrocellu- 
lose, and immunostained. As shown in Fig. 1, Ab 1-1.1 binds 
specifically to the beta subunlt of purified brain tubulin (lane 
A'). Likewise, when total mouse fibroblast proteins were im- 
munostained with Ab 1-1.1, only a single band corresponding 
to the beta-tubulin subunit was labeled (lane B'). 
Binding of  Radiolabeled Ab 1-1.1 to Cytoskeletons 
To obtain a translationally radiolabeled antibody probe for 
microtubules, we incubated log phase hybridoma 1-1.1 cells 
in complete RPMI 1640 medium containing labeled amino 
acids. The supernatant culture fluid was then dialyzed exten- 
sively against PBS, filter sterilized, and used directly as a 
source of radioactive antibody for binding experiments, or 
Figure 1. Monoclonal Ab 1-1.1 binds to the beta subunit of tubulin. 
ME fibroblastic cells were rinsed with PBS and dissolved on the 
plate in SDS electrophoresis sample buffer, sonicated to fragment 
the DNA, and heated at 100°C for 2 min. Mouse brain microtubule 
protein purified by three  cycles of polymerization  was pelleted 
through 50% sucrose and separated from MAPs by phosphocellu- 
lose chromatography. Purified brain tubulin (25 lag, lane A) and to- 
tal ME cell proteins (lane B) were subjected to electrophoresis on 
8% polyacrylamide (SDS) slab gels that were either stained with 
Coomassie Blue or Western blotted to nitrocellulose. The nitrocel- 
lulose sheet was soaked for 5 min in 1% Triton X-100 in PBS to re- 
move the SDS, blocked, and immunostained with monoclonal Ab 
1-1.1 as described in Materials and Methods. Lanes A' and B' are 
the Ab 1-1.1 immunoblots corresponding to the Coomassie-stained 
gels in lanes A and B, respectively. The alpha- and beta-subunits 
of  tubulin are indicated, as well as the molecular weight (in kilodal- 
tons) of several protein standards. 
an IgM fraction isolated from hybridoma 1-1.1 supernatant 
(5) was used. 
To examine if radiolabeled Ab  1-1.1 bound specifically, 
ME cytoskeletons were incubated with dilutions of purified 
3H-Ab  1-1.1 alone or in the presence of at least a  100-fold 
excess of unlabeled antibody from ascites serum of a hybrid- 
oma 1-1.1 tumor to determine total and nonspecific binding, 
respectively (Fig.  2  A).  The level of nonspecific binding 
measured in the presence of excess unlabeled antibody was 
equivalent to binding of dilutions of the labeled antibody to 
culture wells without cells. Thus, it is likely that most of the 
nonspecific binding was to the plastic. Because excess unla- 
beled Ab  1-1.1 in  homologous ascites  serum appeared to 
compete with radiolabeled Ab 1-1.1 for binding to extracted 
ME cytoskeletons, the difference between these two sets of 
values in Fig. 2 A represented specific Ab 1-1.1 binding. As 
shown in Fig. 2 B, this specific Ab 1-1.1 binding was satura- 
ble. A  Scatchard-type analysis of the data (inset) indicated 
that the antibody bound with a single affinity to tubulin sug- 
gesting that this type of analysis could be used to determine, 
by extrapolation, the total number of antigenic binding sites 
per cell. 
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Figure 2. (A) Total and nonspecific binding 
of 3H-labeled  monoclonal antitubulin  Ab 
1-1.1 to detergent-extracted  cytoskeletons  of 
ME cells.  Purified  3H-labeled monoclonal 
Ab  1-1.1 was serially  diluted  as  indicated 
and incubated overnight with formaldehyde- 
fixed  cytoskeletons  of detergent-extracted 
ME cells. The total radioactivity remaining 
bound after rinsing is shown (e).  To esti- 
mate  the  nonspecific  component  of this 
binding,  ME cytoskeletons  were incubated 
in parallel  with an identical  set of labeled 
antibody dilutions in the presence of a large 
excess of unlabeled Ab 1-1.1 from an IgM 
fraction of ascites serum (0). Values shown 
are the mean 4- SD of triplicate  assays. (B) 
Specific  binding of Ab  1-1.1 to ME eyto- 
skeletons.  Specifically  bound 3H-Ab  1-1.1 
was calculated  as the difference  between the two sets of values in A. A Scatchard-type plot of the specific binding of antitubulin  Ab 1-1.1 
to extracted  ME cytoskeletons  is shown in the inset.  Note that the specific binding of Ab 1-1.1 to the cytoskeletons  is saturable  and of a 
single  apparent affinity. 
Competition for Ab I-I.1 Binding to Cytoskeletons 
by Nonhomologous Ascites Serum Protein or 
by Purified Tubulin 
To determine if proteins other than the specific antibody in 
the ascites serum might have inhibited labeled Ab 1-1.1 bind- 
ing, we compared the inhibition of binding caused by homol- 
ogous  and  nonhomologous  ascites  serum  (Fig.  3  A).  As 
shown, as little as 20 ttg of  homologous ascites serum protein 
blocked  ~60%  of 35S-labeled  Ab  1-1.1 binding  while  as 
much as 0.7 mg of nonhomologous ascites serum protein did 
not compete  with Ab  1-1.1 for binding to human foreskin 
(HF)  cytoskeletons.  This  competition  experiment  demon- 
strated  that  specific Ab  1-1.1 binding  was inhibited  by the 
specific antibody in ascites fluid and not by other ascites se- 
rum proteins. It should be noted that the amount of homolo- 
gous ascites serum normally added for nonspecific binding 
determinations  in  24-well  plates  was  1.2  mg/well  which 
causes maximum inhibition of Ab 1-1.1 binding. 
To test if the apparent specific binding to cytoskeletons ac- 
tually  represented  binding  to  tubulin,  we  determined  if 
preabsorption  of 35S-labeled  Ab  1-1.1 with  purified  brain 
tubulin could eliminate this specific component. As shown 
in  Fig.  3  B,  specific binding  of Ab  1-1.1 was  blocked by 
preabsorption with 9 ~tg/ml or more of exogenous tubulin to 
the  same  extent  as  by  homologous  ascites  serum.  These 
results together confirm that the difference between total and 
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Figure 3. (,4) Specific binding of Ab 1-1.1 is blocked by unlabeled 
Ab 1-1.1 ascites serum, but not by an unrelated  ascites serum. Ex- 
tracted cytoskeletons  of HF cells were incubated with a 1:8 dilution 
of dialyzed culture supernatant  containing  35S-labeled Ab 1-1.1 in 
the presence of  various amounts of homologous (•) or nonhomolo- 
gous (0) ascites  serum protein.  The bound radioactivity was then 
determined. (B) Specific binding of Ab 1-1.1 is blocked by preincu- 
bation with exogenous tubulin.  Aliquots of dialyzed culture super- 
natant  fluid containing 35S-labeled monoclonal Ab 1-1.1 were ab- 
sorbed with the concentrations of  phosphocellulose-purified  bovine 
brain tubulin  indicated  before binding to HF cytoskeletons  (•). A 
control without exogenous  tubulin,  but incubated  in the presence 
of Ab 1-1.1 ascites  serum is shown  (0).  Note that the amount of 
nonspecific  binding was  the same,  whether Ab  1-1.1 binding to 
microtubules was competed by excess antigen (brain tubulin) or ex- 
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Figure 4. 3H-labeled Ab 1-1.1 binding to extracted cytoskeletons  of 
ME cells pretmated with various concentrations of colchicine.  ME 
cells  were pretreated  for 1 h  with the concentrations of colchi- 
cine indicated,  detergent-extracted,  formaldehyde-fixed,  and 3H- 
Ab 1-1.1 binding to cytoskeletons of these cells was then measured. 
Specific binding is shown for a single dilution (1:8) of labeled anti- 
body. Values shown are the mean  4- SD of triplicate  assays. 
The Journal  of Cell  Biology,  Volume  103,  1986  1036 Figure 5. Antitubulin Ab 1-1.1 immunoftuorescence staining of colchicine-treated ME cells. ME cells were pretreated with colchicine for 
1 h before immunofluorescence analysis as described in Materials and Methods. Colchicine concentrations were as follows: (a) none; (b) 
0.1 gM; (¢) 0.3 BM; (d) 1 laM, (e) 10 gtM; (f) 60 I.tM. The cells shown are representative of each population. Bar, 25 p.m. 
nonspecific binding in this assay represented specific binding 
of radioactive Ab  1o1.1 to cytoskeletal tubulin. 
Binding of  Ab 1-1.1 As a Function of Cytoskeletal 
Microtubule Content 
To establish that the binding of labeled Ab 1-1.1 measured the 
size of the cytoskeletal mbulin pool, we assayed the Ab 1-1.1 
binding to cells treated with drugs that alter microtubule con- 
tent. First, ME cells were pretreated with colchicine concen- 
trations from 0.03 to 60 BM to induce various degrees of  depo- 
lymerization of cytoplasmic microtubules before the binding 
assay. As shown in Fig. 4, a decrease in radiolabeled Ab 1-1.1 
binding was detected when ME cells were pretreated with as 
little as 0.1 ~VI colchicine and was maximal at drug concen- 
trations from 1 to 60 BM. In various experiments, this de- 
crease ranged from 78 to 87 % of the total specific binding. 
Consistent with these results, parallel immunofluorescence 
studies showed that slight depolymerization was first seen in 
ME cells pretreated with 0.1 ~  colchicine (Fig. 5 b), partial 
depolymerization was  evident in  cells pretreated with 0.3 
gM colchicine (Fig. 5 c), and maximum depolymerization 
was observed in cells pretreated with  1-60 ~tM colchicine 
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Colchicine  [3H]Thymidine  % of 
concentration  per well  control 
#M  cpm  x  IO  -~ 
None  144  +  6  100 
0.03  146  +  6  I01 
0.1  142  +  14  99 
0.3  158  5:5  110 
1  140  5:2  97 
3  134  +  1  93 
10  154  5:5  107 
60  130  4-  11  90 
ME cells were grown in a 24-well plate in medium containing [3H]thymidine 
for 48 h  to uniformly label the cell population. Cells were then brought to 
quiescence as in Materials and Methods and incubated with the colchicine con- 
centrations indicated for 1 h at 37"C. The cells were extracted and fixed as in 
antibody binding assays. The [3I-I]thymidine-labeled DNA was removed from 
each well with 1.0 N NaOH and the radioactivity  determined by liquid scintil- 
lation counting, 
(Fig. 5, d-f). It should be noted that even at the highest col- 
chicine concentrations these cells appear to have a popula- 
tion of drug-stable microtubules (Fig. 5, d-f) that may ac- 
count for some of the residual (13-22 %) specific binding of 
Ab 1-1.1 to these colchicine-treated cells. Other experiments 
showed that colchicine pretreatment, extraction, and fixation 
did not cause release of the cells from the assay plate (Table 
I). In addition, Scatehard-type analysis of the binding of Ab 
1-1.1 (as shown in Fig. 2) to cytoskeletons of  control ME cells 
and of ME cells pretreated with  1 laM colchicine demon- 
strated that the decrease in Ab 1-1.1 binding was due to a de- 
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Figure 6. 3H-labeled Ab 1-1.1 binding to extracted cytoskeletons of 
ME cells pretreated with various concentrations of  taxol and colchi- 
cine in combination. ME cells were preincubated for 1 h with the 
concentrations of colchicine indicated on the abscissa and with the 
concentrations of taxol (ttg/rrd) indicated to the right of each curve. 
The cells were then extracted, fixed, and radioactive Ab 1-1.1 bind- 
ing was measured in triplicate assays. Total (e) and nonspecific (0) 
binding of 3H-Ab 1-1.1 is shown for a single labeled antibody dilu- 
tion (1:8). 
crease in the number of  antigenic  binding sites  rather  than 
to a change in affinity  (data  not shown). Thus, the drug- 
induced decrease in specific  Ab 1-1.1  binding appears to 
reflect an actual decrease in the amount of  polymerized tubu- 
lin.  Therefore, these results demonstrate that most of the 
specific binding of Ab 1-1.1 represents binding to microtubu- 
lar tubulin. 
If the decrease in radioactive Ab 1-1.1 binding in colchi- 
cine-trcated cells is due to a loss of microtubules, it should 
be possible to block this decrease by stabilizing microtubules 
with taxol. We, therefore, pretreated ME cells with various 
concentrations of taxol and colchicine in combination before 
measuring Ab 1-1.1 binding. As shown in Fig. 6, taxol treat- 
ment alone caused an increase in Ab 1-1.1 binding of •50%. 
Taxol treatment of ME cells also prevented the colchicine- 
induced decrease in 3H-Ab 1-1.1 binding to cytoskeletons in 
a manner dependent on taxol concentration. These results 
correlate with immunofluorescence studies (9) of ME cells 
treated with I taM colchicine together with various taxol con- 
centrations. Taxol concentrations of <5 ttg/ml stabilized few 
microtubules against disruption by 1 ttM colchicine. In con- 
trast, 5  ttg/ml of taxol caused substantial stabilization and 
10-20 ttg/ml of taxol prevented microtubule disruption by 
1 ttM colchicine. Therefore, these results further indicate 
that radioactive Ab 1-1.1 binding is proportional to changes 
in cytoskeletal tubulin. 
In addition to measuring drug-induced loss of microtu- 
bules, we tested the ability of  this assay to measure regrowth 
of microtubulcs.  We treated ME cells with colcemid and 
used  the  radiolabeled  Ab  1-1.1 binding  assay  to  monitor 
microtubule reassembly after removal of the drug. ME cells 
were treated with 1 taM colcemid for 2 h, the cells returned 
to fresh serum-free medium, and 3H-Ab  1-1.1 binding was 
measured at various times after colcemid removal. As shown 
in Fig. 7, Ab 1-1.1 binding returned to control levels by 2 h 
after colcemid removal. Consistent with these results, our an- 
titubulin immunofluorescence experiments (Crossin, K. L., 
and D. H. Carney, manuscript in preparation) with ME cells 
have shown that microtubule reassembly after removal of 
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Figure  7.  Etfect of colcemid treatment and removal on 3H-labeled 
Ab 1-1.1 binding to ME cytoskeletons. ME cells were treated with 
2 gM colcemid (C) for I h, 2 h, or left untreated. Alternatively, 
the cells were treated with 2 ttM colcemid for 2 h, the medium con- 
taining the colcemid removed (R), and the cells incubated in serum- 
free medium  for the  times  indicated  before  binding  analysis. 
Specific binding for a 1:8 antibody dilution is plotted. Values shown 
are the mean  +  SD of triplicate assays. 
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1-1.1 Molecules Bound to Cytoskeletons of 
Different Cell Types 
Antibody  1-1.1 
molecules bound* 
Cell type  (per eell)¢ 
ME  16  x  106 
HF  10  x  106 
3T3  6.1  x  106 
The procedure  for 3H-Ab 1-1.1 binding  assays  and  Scatchard-type  analysis 
was described  in the legend to Fig.  2. 
* The specific activity of purified 3H-Ab 1-1.1 was determined as described in 
Materials and Methods. 
The total number of cells per 24-well plate after extraction and fixation was 
determined by counting nuclei within a Zeiss ocular grid from six fields. The 
ocular grid was calibrated with a stage micrometer (American Optical, Buffalo, 
NY). 
colcemid appears complete within 2 h after the drug is re- 
moved. Thus, in three different types of experiments where 
microtubule content was manipulated by various drug treat- 
ments, we observed a correlation between Ab 1-1.1 binding 
and the extent of microtubule polymerization. 
Quantitation of  Cytoskeletal Tubulin in Cultured Cells 
The results presented above show that the specific binding of 
radioactive antitubulin antibodies to cytoskeletons extracted 
under  microtubule-stabilizing  conditions  can  be  used  to 
measure relative changes in cytoskeletal tubulin content in 
cultured cells. Using Scatchard-type analysis of radioactive 
Ab lad binding, it is possible to determine the total number 
of antibody molecules that can bind per cytoskeleton. De- 
pending on the stoichiometry of antibody binding, this num- 
ber can then be used as a measure of the number of tubulin 
dimers present as microtubular tubulin. To test this approach 
to quantitation we determined the specific activity of  purified 
3H-Ab  1-1.1 and  the  number  of cells per  multiwell plate 
well,  and  performed Scatchard-type analysis  of Ab  1-1.1 
binding to ME, HE and mouse 3T3 cells (Table H). These 
results show that ME cells bind "02.6 times the number of 
Ab  1-1.1 molecules as mouse 313 cells and "01.6 times the 
number as HF cells. Assuming a constant ratio of  bound anti- 
body to cytoskeletal tubulin, the results in Table II indicate 
that these fibroblastic cell populations differ as much as 2.6- 
fold in their content of cytoskeletal tubulin. Immunofluores- 
cence micrographs of these cells demonstrate that the differ- 
ences in antibody binding could reflect differences in cell 
size (compare ME and 313,  Fig.  8,  a  and c) or apparent 
differences in microtubule number or density (compare ME 
and HE  Fig.  8,  a  and b).  It should be noted that similar 
results were obtained with two separate preparations of 3H- 
Ab  1-1.1. 
Hiller and Weber (16), using a radioimmunoassay for tubu- 
lin, report extraction of  26 million tubulin dimers per normal 
3T3 cell and suggest that 40% of this cellular tubulin, or "010 
million  dimers,  would  be  polymerized into  microtubules 
during interphase. We calculate that each cytoskeleton of our 
quiescent 313 cells binds ,o6.1 million Ab 1-1.1 molecules at 
saturation. By comparing these values for 3T3 cells, we esti- 
mate that the stoichiometry of Ab 1-1.1 binding in our system 
is "01.6 cytoskeletal tubulin heterodimers per IgM molecule. 
It should be noted,  however, that our cells were growth- 
arrested in serum-free medium and, therefore, direct com- 
parison with published values for nonarrested 313 ceils may 
be premature.  Nevertheless, the close agreement between 
this published value for cytoskeletal tubulin and our determi- 
nation of maximal Ab 1-1.1 binding suggests that with known 
binding  stoichiometry, this  direct antibody binding  assay 
may  be  quite  useful  in  quantitating  absolute  amounts  of 
cytoskeletal tubulin in cultured cells. 
Figure 8.  Ab  1-1.1 immunofluorescence staining of ME, HE and mouse 3T3 cells. Immunofluorescence analysis was as described in 
Materials and Methods. (a) ME; (b) HF; (c) mouse 3T3. Bar, 25 gm. 
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We have developed a simple, direct antibody binding assay 
for cytoskeletal tubulin in populations of cultured cells. This 
assay is based upon: (a) the ability to differentially extract 
the pool of free tubulin from the cells, leaving the microtu- 
bules with the insoluble cytoskeleton, and (b) the use of a 
monoclonal antibody to a tubulin subunit, whose saturation 
level  of specific  binding  to  the  cytoskeletons should be 
directly related to the number of tubulin units in the microtu- 
bules. 
Monoclonal antibody (Ab 1-1.1), specific for the beta sub- 
unit of tubulin, was translationally radiolabeled and used as 
a  probe for cytoskeletal tubulin within detergent-extracted 
cytoskeletons. Specific binding of radiolabeled Ab 1-1.1 was 
saturable and of a  single affinity.  Several types of experi- 
ments indicated that this specific binding was proportional 
to the amount of  microtubule protein within the cytoskeleton. 
First, pretreatment of ME cells with colchicine decreased 
the amount of antibody bound to cytoskeletons. This de- 
crease correlated with the loss of microtubules as detected 
by immunofluorescence  microscopy. Second, the colchicine- 
induced decrease in antibody binding could be blocked by 
pretreating ME ceils with the microtubule-stabilizing drug, 
taxol, in combination with colchicine. The taxol concentra- 
tions that blocked the colchicine-induced decrease in Ab 
1-1.1 binding have been previously shown to stabilize micro- 
tubules against disruption by colchicine as  visualized by 
immunofluorescence  microscopy  (9).  In  addition,  taxol 
treatment alone  caused an  increase  in  Ab  1-1.1 binding. 
Third, the radiolabeled Ab I-1.1 binding assay was used to 
detect microtubule disassembly induced by colcemid, and to 
monitor the time course of recovery of microtubules after 
removal of the drug. Microtubule recovery was complete by 
,~2 h after colcemid removal as determined by Ab 1-1.1 bind- 
ing or immunofluorescence analysis (Crossin,  K.  L., and 
D.H.  Carney,  manuscript  in  preparation).  Fourth,  we 
demonstrated with the  Ab  1-1.1 binding assay that three 
different cell types, ME cells, HF cells, and mouse 3T3 cells, 
differed from each other in the amount of  cytoskeletal  tubulin 
present  per  cell.  These  differences also  correlated  with 
differences among the three cell types in the appearance of 
the  cytoplasmic  microtubule  complex  observed  by  im- 
munofluorescence microscopy. Thus, in all cases, changes 
in  the  amount of radiolabeled Ab  1-1.1 binding  reflected 
changes  in  the  amount of microtubular tubulin  in  these 
cytoskeletons. 
A direct radiolabeled antibody binding procedure for as- 
saying microtubule protein has a number of advantages for 
estimating changes in cytoskeletal tubulin content within cul- 
tured  cells.  In  previous  direct  antibody  binding  assays, 
cytoskeletal antigens have been visualized in individual cells 
by either immunofluorescence or immunocytochemical stain- 
ing. This new assay allows quantification of changes in the 
polymerization state of tubulin in whole populations of cells, 
and does not require that cells be grown in sparse culture or 
that they have a flat morphology in culture. Moreover, the 
use of multiwell culture plates allows an entire experiment 
to be carried out under identical culture, binding, and rinsing 
conditions. 
A  different type of direct assay for polymerized tubulin 
within cultured cells uses the binding of radiolabeled taxol, 
a drug that binds to intact microtubules (27, 28).  Although 
this  is  a  promising  approach  to  quantitating cytoskeletal 
tubulin, functional disadvantages of this assay procedure in- 
clude the scarcity of taxol and the necessity to custom radio- 
label the drug and then characterize each batch of labeled 
taxol for suitability in binding assays. In addition, taxol has 
been shown to bind preferentially to certain types of microtu- 
bules (29). Our assay shares with the taxol assay the advan- 
tage of direct binding to cytoskeletal microtubules, but has 
the advantage of potentially unlimited availability of both ra- 
diolabeled and unlabeled forms of reagent. The assay pro- 
cedure  described here  for cytoskeletal tubulin  should be 
directly adaptable  for  any  other  cytoskeletal antigen for 
which monoclonal antibodies are available or can be gener- 
ated. This should be particularly useful for assaying proteins 
for which no specific drugs comparable to colchicine or taxol 
exist. 
Differential extraction procedures have been developed for 
the indirect determination of microtubular tubulin content as 
the difference between the "unpolymefized" soluble tubulin 
pool and a total pool consisting of all tubulin that can be 
made  soluble under microtubule-destabilizing conditions. 
Determination of the soluble tubulin in such indirect proce- 
dures has been accomplished by colchicine binding assays 
(3, 4, 22, 25, 26, 30-33, 40).  This determination might be 
improved by using  immunochemical assay methods.  Re- 
cently, an ELISA "sandwich" procedure has been described 
for quantitation of the pool of soluble tubulin from cultured 
myocytes (34). This ELISA assay has the advantage over col- 
chicine binding assays of stability of the binding property, 
and has been shown to be linear in the range of 10-500  ng 
of tubulin.  Conventional  radioimmunoassays for  tubulin 
have also been developed in several laboratories and used for 
quantitation of tubulin in cells and tissues (15, 16, 18, 19, 39). 
Like the ELISA assay and radioimmunoassay, our assay has 
the advantage over colchicine binding assays that the prop- 
erty being measured is not labile and, therefore, does not re- 
quire  large extrapolative corrections to the binding data. 
Moreover, as opposed to indirect assays, the fixed cytoskele- 
tons form an immobile phase making the binding and rinsing 
steps for large numbers of samples quite simple. However, 
indirect determinations of cytoskeletal tubulin, based upon 
colchicine  binding  or  immunochemical determination of 
soluble tubulin, will remain uniquely powerful tools in as- 
saying  whole  tissue  homogenates  as  opposed  to  cell 
monolayers in culture. 
The  quantitation of binding  of antitubulin antibody to 
cytoskeletons, as presented here, appears to be proportional 
to the content of  cytoskeletal  tubulin. The number of Ab 1-1.1 
specific epitopes should equal the number of tubulin hetero- 
dimers. However,  several factors may prevent direct quanti- 
tation of cytoskeletal tubulin molecules at this stage of devel- 
opment of the antibody binding assay. Absolute quantitation 
would require that all the epitopes be available for antibody 
binding and that the stoichiometry of binding could be de- 
fined. For this purpose, radiolabeled monovalent Fab frag- 
ments from an IgG would have the advantage of easier access 
to the epitope as well as a defined 1:1  stoichiometry. Our 
monoclonal Ab 1-1.1, being an IgM antibody, is not a good 
candidate for production of such monovalent Fab fragments. 
Given the nature of a complex insoluble antigen such as the 
cytoskeleton,  some  steric  hinderance  to  binding  of even 
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son of Hiller and Weber's (16) estimate of polymerized tubu- 
lin in 3T3 cells and our value for the number of Ab  1-1.1 
molecules  bound  by  3T3  cells  suggests  that the  overall 
stoichiometry  for  binding  in  our  system  approaches  1.6 
moles of tubulin heterodimers per mole of IgM, which may 
indicate that most of the microtubular tubulin is,  in fact, 
available for quantitation by this type of assay. 
We have recently demonstrated that at least two antigenic 
types  of  cytoplasmic  microtubules  coexist  within  single 
fibroblastic cells (37).  These two microtubule classes were 
distinguished  by  immunofluorescence  procedures  using  a 
unique monoclonal antibody to alpha-tubulin (Ab 1-6.1). By 
incorporating such discriminating antitubulin reagents into 
the radiolabeled antibody binding assay as described here, 
it  should  be possible with this  assay to  observe  changes 
within subpopulations of microtubules (or individual isotu- 
bulins within microtubules)  independent of changes in the 
total microtubule pool. We feel that such a radiolabeled anti- 
body  binding  assay, in  conjunction  with  immunofluores- 
cence studies based upon monoclonal  antibodies of the ap- 
propriate specificity, will prove invaluable in dissecting  the 
functional  heterogeneity  of  the  cytoplasmic  microtubule 
complex. 
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